BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15529311)

  • 1. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V; Arrigo C; Righi M
    Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
    Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET
    Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
    Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
    Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
    Falchi L; Gunnellini M; Ferranti L; Liberati AM
    Clin Neurol Neurosurg; 2012 Dec; 114(10):1376-8. PubMed ID: 22516417
    [No Abstract]   [Full Text] [Related]  

  • 10. [Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
    Matsko MV
    Vopr Onkol; 2012; 58(3):425-8. PubMed ID: 22888663
    [No Abstract]   [Full Text] [Related]  

  • 11. [Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
    Wakabayashi T
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):938-40. PubMed ID: 19579330
    [No Abstract]   [Full Text] [Related]  

  • 12. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
    Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
    Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is protracted low-dose temozolomide feasible in glioma patients?
    Wong ET
    Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
    Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
    De Vita S; De Matteis S; Laurenti L; Chiusolo P; Reddiconto G; Fiorini A; Leone G; Sica S
    Ann Hematol; 2005 Oct; 84(11):760-2. PubMed ID: 16044311
    [No Abstract]   [Full Text] [Related]  

  • 17. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
    Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line therapy with temozolomide induces regression of primary CNS lymphoma.
    Herrlinger U; Küker W; Platten M; Dichgans J; Weller M
    Neurology; 2002 May; 58(10):1573-4. PubMed ID: 12034807
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma.
    Mateos ME; López-Laso E; Izquierdo L; Pérez-Navero JL; García S; Garzás C
    Pediatr Int; 2011 Apr; 53(2):261-3. PubMed ID: 21501315
    [No Abstract]   [Full Text] [Related]  

  • 20. Taming glioblastoma by targeting angiogenesis: 3 years later.
    Wong ET; Brem S
    J Clin Oncol; 2011 Jan; 29(2):124-6. PubMed ID: 21135277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.